Lavipharm S.A. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was EUR 21.2 million compared to EUR 19.55 million a year ago. Net income was EUR 1.9 million compared to EUR 2.6 million a year ago.

Basic earnings per share from continuing operations was EUR 0.1116 compared to EUR 0.1524 a year ago.